Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotatercept PK and Safety in Healthy Chinese Participants
NCT06843460Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2023
- Primary completion
- May 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sotatercept in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience an Adverse Event (AE) at 120 days, Number of Participants Who Discontinue Study Due to an AE at 120 days and 8 more. Started Nov 2023; status: completed.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06843460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06843460.